Measuring inhibition of HIV replication by ex vivo CD8+ T cells

Journal of Immunological Methods

Volumn 404, Issue 1, 2014, Pages 71-80

  Slichter, Chloe K ^a   Friedrich, David P ^a   Smith, Rebecca J ^a   Walsh, Paula N ^a   Mize, Greg ^a   Czartoski, Julie L ^a   McElrath, M Juliana ^a,b   Frahm, Nicole ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CD8 T cells; HIV suppression; Vaccine induced T cell responses; Viral inhibition

Indexed keywords

GAMMA INTERFERON;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CD8 T CELLS; HIV SUPPRESSION; VACCINE-INDUCED T-CELL RESPONSES; VIRAL INHIBITION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENES, REPORTER; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOASSAY; LUCIFERASES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PRIMARY CELL CULTURE; SENSITIVITY AND SPECIFICITY; VIRUS REPLICATION;

EID: 84896727435     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.12.006     Document Type: Article

References (38)

1. + T-cells. Blood 2006, 107:4781.
2. + T cells. Evidence for a soluble inhibitor. J. Immunol. 1990, 144:2961.
3. Bull M., Lee D., Stucky J., Chiu Y.L., Rubin A., Horton H., McElrath M.J. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J. Immunol. Methods 2007, 322:57.
4. + T memory phenotypes in subtype C HIV-1 infection with viral set point. J. Immunol. 2009, 182:4751.
5. + T cells in primary HIV-1 infection. J. Virol. 2003, 77:6867.
6. + T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res. Hum. Retroviruses 1993, 9:1079.
7. Cheng-Mayer C., Levy J.A. Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann. Neurol. 1988, 23:S58. (Suppl.).
8. Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004, 32:1792.
9. Edmonds T.G., Ding H., Yuan X., Wei Q., Smith K.S., Conway J.A., Wieczorek L., Brown B., Polonis V., West J.T., Montefiori D.C., Kappes J.C., Ochsenbauer C. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010, 408:1.
10. + T lymphocyte function in HIV-infected persons. J. Immunol. Methods 2007, 327:75.
11. Forestell S.P., Dando J.S., Bohnlein E., Rigg R.J. Improved detection of replication-competent retrovirus. J. Virol. Methods 1996, 60:171.
12. Frahm N., DeCamp A.C., Friedrich D.P., Carter D.K., Defawe O.D., Kublin J.G., Casimiro D.R., Duerr A., Robertson M.N., Buchbinder S.P., Huang Y., Spies G.A., De Rosa S.C., McElrath M.J. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J. Clin. Invest. 2012, 122:359.
13. Freel S.A., Lamoreaux L., Chattopadhyay P.K., Saunders K., Zarkowsky D., Overman R.G., Ochsenbauer C., Edmonds T.G., Kappes J.C., Cunningham C.K., Denny T.N., Weinhold K.J., Ferrari G., Haynes B.F., Koup R.A., Graham B.S., Roederer M., Tomaras G.D. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 2010, 84:4998.
14. Gao F., Yue L., Craig S., Thornton C.L., Robertson D.L., McCutchan F.E., Bradac J.A., Sharp P.M., Hahn B.H. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. AIDS Res. Hum. Retroviruses 1994, 10:1359.
15. Gartner S., Markovits P., Markovitz D.M., Kaplan M.H., Gallo R.C., Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986, 233:215.
16. Gray C.M., Mlotshwa M., Riou C., Mathebula T., de Assis Rosa D., Mashishi T., Seoighe C., Ngandu N., van Loggerenberg F., Morris L., Mlisana K., Williamson C., Karim S.A. Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J. Virol. 2009, 83:470.
17. Hersperger A.R., Pereyra F., Nason M., Demers K., Sheth P., Shin L.Y., Kovacs C.M., Rodriguez B., Sieg S.F., Teixeira-Johnson L., Gudonis D., Goepfert P.A., Lederman M.M., Frank I., Makedonas G., Kaul R., Walker B.D., Betts M.R. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010, 6:e1000917.
18. Julg B., Williams K.L., Reddy S., Bishop K., Qi Y., Carrington M., Goulder P.J., Ndung'u T., Walker B.D. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J. Virol. 2010, 84:5540.
19. Lieberman J. Tracking the killers: how should we measure CD8 T cells in HIV infection?. AIDS 2004, 18:1489.
20. Lole K., Bollinger R., Paranjape R., Gadkari D., Kulkarni S., Novak N., Ingersoll R., Sheppard H., Ray S. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J. Virol. 1999, 73:152.
21. + cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res. Hum. Retroviruses 1992, 8:1039.
22. Malhotra U., Holte S., Dutta S., Berrey M.M., Delpit E., Koelle D.M., Sette A., Corey L., McElrath M.J. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J. Clin. Invest. 2001, 107:505.
23. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., Casimiro D.R. HIV-1 vaccine-induced immunity in the test-of-concept Step study: a case-cohort analysis. Lancet 2008, 372(9653):1894-1905. 10.1016/S0140-6736(08)61592-5.
24. Michael N.L., Herman S.A., Kwok S., Dreyer K., Wang J., Christopherson C., Spadoro J.P., Young K.K., Polonis V., McCutchan F.E., Carr J., Mascola J.R., Jagodzinski L.L., Robb M.L. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J. Clin. Microbiol. 1999, 37:2557.
25. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29:1009.
26. Pantaleo G., Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 2004, 10:806.
27. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209.
28. + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 2007, 178:2746.
29. Saez-Cirion A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., Barre-Sinoussi F., Delfraissy J.F., Sinet M., Pancino G., Venet A. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6776.
30. + T-cell responses. Nat. Protoc. 2010, 5:1033.
31. Spentzou A., Bergin P., Gill D., Cheeseman H., Ashraf A., Kaltsidis H., Cashin-Cox M., Anjarwalla I., Steel A., Higgs C., Pozniak A., Piechocka-Trocha A., Wong J., Anzala O., Karita E., Dally L., Gotch F., Walker B., Gilmour J., Hayes P. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 2010, 201:720.
32. Toso J.F., Chen C.H., Mohr J.R., Piglia L., Oei C., Ferrari G., Greenberg M.L., Weinhold K.J. Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J. Infect. Dis. 1995, 172:964.
33. Vaccari M., Poonam P., Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev. Vaccines 2010, 9:997.
34. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234:1563.
35. Walsh P.N., Friedrich D.P., Williams J.A., Smith R.J., Stewart T.L., Carter D.K., Liao H.X., McElrath M.J., Frahm N., Network N.H.V.T. Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials. J. Immunol. Methods 2013, 394:84.
36. + cells without eliminating the infected cells from culture. Cell. Immunol. 1990, 128:628.
37. Yang O.O. Will we be able to 'spot' an effective HIV-1 vaccine?. Trends Immunol. 2003, 24:67.
38. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 1997, 71:3120.